Spotlight
Specialty
Partners
CME/CE
Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia
Armin Ghobadi, MD, and fellow panelists discuss new data concerning patients most at risk for developing ALL.
EP: 1.Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia
EP: 2.Differentiating Subtypes of Acute Lymphoblastic Leukemia
Now Viewing
EP: 3.Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia
EP: 4.Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia
EP: 5.Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia
EP: 6.Treatment Options for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Frontline Setting
EP: 7.The Evolving Treatment Paradigm for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
EP: 8.Recently Presented Data Informing the Treatment of Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
EP: 9.Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
EP: 10.CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia
EP: 11.Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia
EP: 12.Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia
EP: 13.Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia
EP: 14.On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape
Related Videos
Related Content
